Friday, October 2, 2020

Blood-based gene expression signature associated with metastatic castrate-resistant prostate cancer patient response to abiraterone plus prednisone or enzalutamide | Prostate Cancer and Prostatic Diseases

Blood-based gene expression signature associated with metastatic castrate-resistant prostate cancer patient response to abiraterone plus prednisone or enzalutamide | Prostate Cancer and Prostatic Diseases

No comments: